Research
Hormonal
Elevated levels of C-reactive protein (CRP) and Serum Amyloid A (SAA) serve as independent predictors of cardiovascular events and are directly linked to obesity-induced inflammation.
High CRP and SAA levels are warning signs of inflammation linked to excess body fat. Monitoring these markers can help assess cardiovascular risk, and reducing body fat can lower these levels.
StrongSupportsVERY_HIGH confidence
More than 20 prospective epidemiologic studies have demonstrated that high-sensitivity CRP is an independent predictor of myocardial infarction, stroke, peripheral arterial disease, and sudden cardiac death... SAA elevation can predict cardiovascular events analogously with or even better than CRP by itself.
Why this rating
Cited as having strong prospective epidemiologic evidence.
Source
Inflammation, a Link between Obesity and Cardiovascular Disease
Zhaoxia Wang et al. · Mediators of Inflammation · 2010
DOI 10.1155/2010/535918
narrative_reviewCited 413×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Obesity induces chronic low-grade systemic inflammation through adipose tissue-derived cytokines (such as TNF-α, IL-6, and CRP), which accelerates atherosclerosis and increases the risk of cardiovascular disease.Good
- Adiponectin levels decrease in obesity and contribute to cardiovascular risk by failing to provide anti-inflammatory and anti-atherogenic protection to the vessel wall.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →